文献速递生殖医学

多囊卵巢综合征和/或稀发排卵女性来曲唑刺激与人工周期冻融胚胎移植周期的生殖结局:系统综述与荟萃分析

Reproductive outcomes after letrozole stimulated versus artificial frozen-thawed embryo transfer cycles in women with PCOS and/or oligo-anovulation: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2025-01-01

该系统综述与荟萃分析检索至2024年6月,纳入15项观察性研究和2项随机对照试验,比较来曲唑刺激冻融胚胎移植与人工周期冻融胚胎移植在多囊卵巢综合征和/或排卵障碍女性中的生殖、产科和新生儿结局。荟萃分析显示来曲唑组活产几率略高(OR 1.37,95%CI 1.21-1.56),妊娠丢失、妊娠期高血压疾病和大于胎龄儿风险较低,但证据确定性低。

要点

  • 来曲唑冻融胚胎移植活产几率略高于人工周期(OR 1.37,95%CI 1.21-1.56),但一项随机对照试验未显示优势。
  • 来曲唑组妊娠丢失(OR 0.63,95%CI 0.51-0.78)、妊娠期高血压疾病(OR 0.70,95%CI 0.58-0.84)和大于胎龄儿(OR 0.75,95%CI 0.67-0.85)风险较低。
  • 所有结局的证据确定性均为低,需更多设计良好的随机对照试验证实。

核心结论

  • 与人工周期冻融胚胎移植相比,来曲唑冻融胚胎移植可能略微改善生殖结局并降低某些产科并发症风险,尤其在稀发排卵女性中。
  • 证据质量仍低,需要更多设计良好的随机对照试验来证实这些发现。
  • 在等待进一步数据期间,来曲唑冻融胚胎移植可作为排卵障碍女性人工周期冻融胚胎移植的可行替代方案推荐。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Cochrane和ClinicalTrials.gov数据库至2024年6月。
  • 纳入15项观察性研究和2项随机对照试验,共涉及8307名接受来曲唑冻融胚胎移植(±额外促性腺激素)的女性和16940名接受人工周期冻融胚胎移植的女性。
  • 纳入标准为排卵障碍和/或PCOS女性,比较来曲唑冻融胚胎移植与人工周期冻融胚胎移植。
  • 注册号:PROSPERO-CRD42023395117。

主要发现

  • 来曲唑冻融胚胎移植活产几率较人工周期冻融胚胎移植略有统计学显著增加(OR 1.37,95%CI 1.21-1.56),对应风险差8%(95%CI 4%-11%)。
  • 报告活产的一项随机对照试验中,来曲唑冻融胚胎移植与人工周期冻融胚胎移植的活产率相似,不支持来曲唑冻融胚胎移植结局更好。
  • 来曲唑冻融胚胎移植妊娠丢失几率较人工周期冻融胚胎移植降低(OR 0.63,95%CI 0.51-0.78),但报告该结局的两项随机对照试验异质性高,引入结果不确定性。
  • 来曲唑冻融胚胎移植与较低的妊娠期高血压疾病风险(OR 0.70,95%CI 0.58-0.84)和大于胎龄儿风险(OR 0.75,95%CI 0.67-0.85)相关,但妊娠期糖尿病和小于胎龄儿无显著差异。
  • 所有结局的证据确定性均为低。

关键数值与推荐

  • 来曲唑冻融胚胎移植活产OR 1.37(95%CI 1.21-1.56),风险差8%(95%CI 4%-11%)。
  • 来曲唑冻融胚胎移植妊娠丢失OR 0.63(95%CI 0.51-0.78)。
  • 来曲唑冻融胚胎移植妊娠期高血压疾病OR 0.70(95%CI 0.58-0.84)。
  • 来曲唑冻融胚胎移植大于胎龄儿OR 0.75(95%CI 0.67-0.85)。
  • 所有结局证据确定性低。

临床怎么用

  • 对于排卵障碍女性,来曲唑冻融胚胎移植可作为人工周期冻融胚胎移植的可行替代方案推荐,但证据质量低。
  • 需更多设计良好的随机对照试验证实来曲唑冻融胚胎移植的获益。

局限性

  • 所有结局的证据确定性均为低。
  • 报告妊娠丢失的两项随机对照试验异质性高,引入结果不确定性。
  • 需要更多设计良好的随机对照试验来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The global increase in frozen-thawed embryo transfer (FET) cycles has led to a critical evaluation of endometrial preparation methods. While various approaches such as natural or modified natural cycle FET, stimulated FET by use of letrozole (LTZ) and/or gonadotrophins, and artificial cycle (AC) FET, are currently in clinical use, the optimal regimen remains unclear, particularly for women with oligo-anovulation or polycystic ovarian syndrome (PCOS). This systematic review and meta-analysis compares LTZ FET with AC FET regarding reproductive, obstetric, and neonatal outcomes in these populations. OBJECTIVE AND RATIONALE: The aim was to determine whether LTZ FET improves reproductive, obstetric, and neonatal outcomes compared to AC FET in women with ovulatory disorders and/or PCOS. SEARCH METHODS: A comprehensive search of MEDLINE, Cochrane, and ClinicalTrials.gov databases was conducted for studies until June 2024. Eligible studies included women with ovulatory disorders and/or PCOS, comparing LTZ FET to AC FET. Data extraction focused on the live birth rate (LBR), ongoing pregnancy rate, clinical pregnancy rate, pregnancy loss rate, hypertensive disorders of pregnancy (HDP), gestational diabetes mellitus (GDM), birth weight, small for gestational age (SGA), large for gestational age (LGA), and congenital malformations. OUTCOMES: The search identified 74 studies, and included 15 observational studies and two randomized controlled trials (RCTs) meeting the inclusion criteria; the studies encompassed a total of 8307 women treated with LTZ FET (±additional gonadotropin) and 16,940 women treated with AC FET. The meta-analysis comparing LTZ FET to AC FET demonstrated a modest yet statistically significant increase in the odds of LB (OR 1.37, 95% CI 1.21-1.56), corresponding to an 8% risk difference (95% CI 4%-11%). The one RCT that reported on LB yielded a similar LBR for LTZ FET and AC FET, thus did not support a better outcome after LTZ FET. Pregnancy losses, defined either as a loss following a positive serum hCG or following a clinical pregnancy, were compared between LTZ FET and AC FET. The meta-analysis indicated a reduction in the odds of PL with LTZ FET (OR 0.63, 95% CI 0.51-0.78). However, the two RCTs reporting this outcome exhibited high heterogeneity, introducing uncertainty of the result. LTZ FET was associated with lower risks of HDP (OR 0.70, 95% CI 0.58-0.84) and LGA (OR 0.75, 95% CI 0.67-0.85), but no significant differences were observed for GDM or SGA. For all outcomes, the certainty of evidence was low. WIDER IMPLICATIONS: LTZ FET may offer a modest improvement in reproductive outcomes and a lower risk of some obstetric complications compared to AC FET, particularly in women with oligo-anovulation. However, the quality of evidence remains low, and more well-designed RCTs are needed to confirm these findings. While awaiting further data, LTZ FET may be recommended as a viable alternative to AC FET for women with ovulatory disorders. REGISTRATION NUMBER: PROSPERO-CRD42023395117.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Bülow NS, Wissing ML, Macklon N, et al. Reproductive outcomes after letrozole stimulated versus artificial frozen-thawed embryo transfer cycles in women with PCOS and/or oligo-anovulation: a systematic review and meta-analysis. Hum Reprod Update. 2025. PMID: 40420416. doi:10.1093/humupd/dmaf011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。